Piper Sandler raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $232 from $219 and keeps an Overweight rating on the shares. Moving further into 2026, the firm continues to view Jazz as undervalued at a current EV/2026E EBITDA of only seven times in the context of a company that has strong visibility into double-digit overall top-line growth starting in 2027. Though competitive dynamics associated with the oxybate franchise are not lost on Piper, it does not envision said dynamics throwing a wrench into our thinking regarding Jazz’s overall growth profile.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
- Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
- 3 Best Value Stocks with Over 10% Upside in 2026, According to Analysts
- Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
- Jazz Pharmaceuticals Balances Record Gains With Slower 2026